{"product_id":"retatrutide-40mg","title":"Retatrutide 40mg","description":"\u003ch2\u003eRetatrutide 40mg — Triple Agonist Peptide for Research Use\u003c\/h2\u003e\u003cp\u003eRetatrutide 40mg is an advanced experimental peptide developed by Eli Lilly, designed as a once-weekly injectable. It is the first compound to simultaneously activate three key metabolic receptors: GLP-1, GIP, and Glucagon — making it a triple agonist with a unique mechanism of action. This 40mg vial offers a higher-dose option for research applications.\u003c\/p\u003e\u003ch2\u003eHow It Works\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGLP-1 Receptor:\u003c\/strong\u003e Reduces hunger signaling, increases satiety, delays gastric emptying, and improves insulin secretion — the same pathway targeted by Semaglutide.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGIP Receptor:\u003c\/strong\u003e Improves insulin sensitivity, enhances glucose disposal, may reduce GLP-1-associated nausea, and helps preserve lean tissue during weight loss.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlucagon Receptor:\u003c\/strong\u003e Mobilizes stored energy, increases fat oxidation, promotes liver-fat reduction, and raises metabolic rate. GLP-1 and GIP activity offsets glucagon's tendency to raise blood glucose.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eClinical Research Highlights\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e~24% weight loss at 48 weeks in Phase 2 obesity studies\u003c\/li\u003e\n\u003cli\u003e~28.3% weight loss at 80 weeks with 12mg in Phase 3 TRIUMPH-1\u003c\/li\u003e\n\u003cli\u003e~45% of participants achieved ≥30% weight loss\u003c\/li\u003e\n\u003cli\u003eSignificant reductions in visceral and liver fat\u003c\/li\u003e\n\u003cli\u003eImproved triglycerides, insulin sensitivity, and cardiometabolic markers\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eRetatrutide vs. Semaglutide vs. Tirzepatide\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSemaglutide:\u003c\/strong\u003e GLP-1 agonist — strong appetite suppression, moderate fat oxidation\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTirzepatide:\u003c\/strong\u003e GLP-1 + GIP dual agonist — very strong appetite suppression, higher weight loss\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRetatrutide:\u003c\/strong\u003e GLP-1 + GIP + Glucagon triple agonist — highest reported weight loss, greatest fat oxidation studied to date\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFor research purposes only. Not intended for human use. This product is sold strictly for laboratory and scientific research.\u003c\/em\u003e\u003c\/p\u003e","brand":"Rejuve Peptides and Wellness","offers":[{"title":"Default Title","offer_id":42850967617630,"sku":null,"price":200.0,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0661\/6996\/2590\/files\/4fcac78a-4a48-4d66-a0cf-93267532c385.png?v=1780830785","url":"https:\/\/rejuvepeptides.ca\/products\/retatrutide-40mg","provider":"Rejuve Peptides and Wellness","version":"1.0","type":"link"}